13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001778253
Total reported value
$928.2M
$928.2M
95 檔
12.1%
The Q2 2024 SEC filing reveals that Ikarian Capital, LLC held a total portfolio value of $928.2M, covering 95 public equity positions.
During Q2 2024, Ikarian Capital, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including SRPT, CRNX, TARS) accounted for 12.1% of total reported equity market value during Q2 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 10.01% | — | -23.76% | |
| 2 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 8.16% | — | -38.20% | |
| 3 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 6.73% | +0.03% | -1.23% | |
| 4 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 5.63% | -0.94% | EXIT | |
| 5 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 4.34% | — | -44.65% | |
| 6 | ELVN | Enliven Therapeutics Inc | Stock-Other | 4.24% | +0.42% | — | |
| 7 | AMGN | Amgen Inc | Stock-Healthcare | 3.76% | — | -35.17% | |
| 8 | NUVL | Nuvalent Inc-a | Stock-Other | 3.56% | -0.20% | EXIT | |
| 9 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.85% | -6.65% | EXIT | |
| 10 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.85% | — | +46.83% | |
| 11 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.65% | -0.86% | -49.66% | |
| 12 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 2.49% | — | — | |
| 13 | IMVT | Immunovant Inc | Stock-Other | 2.27% | — | +0.36% | |
| 14 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 2.27% | +0.01% | -30.87% | |
| 15 | RNAC | Cartesian Therapeutics Inc | Stock-Other | 2.03% | +0.01% | — | |
| 16 | ✓ | Acelyrin Inc | Stock-Other | 2.01% | — | -5.71% | |
| 17 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.75% | — | — | |
| 18 | PYXS | Pyxis Oncology Inc | Stock-Other | 1.71% | — | +0.22% | |
| 19 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.41% | — | -16.96% | |
| 20 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.31% | — | -33.66% | |
| 21 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.29% | — | — | |
| 22 | CRVO | Cervomed Inc | Stock-Other | 1.26% | — | — | |
| 23 | RZLT | Rezolute Inc | Stock-Other | 1.20% | +0.52% | — | |
| 24 | CYBNEUR | Cybin Inc | Stock-Other | 1.17% | — | — | |
| 25 | INSM | Insmed Inc | Stock-Healthcare | 1.11% | -0.06% | EXIT | |
| 26 | LENZ | Lenz Therapeutics Inc | Stock-Other | 1.09% | — | +140.60% | |
| 27 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.02% | +0.06% | — | |
| 28 | ABEO | Abeona Therapeutics Inc | Stock-Other | 1.01% | — | -19.59% | |
| 29 | INBX | Inhibrx Biosciences Inc | Stock-Other | 1.01% | — | — | |
| 30 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.97% | -11.37% | EXIT | |
| 31 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.90% | — | -46.41% | |
| 32 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.89% | — | -2.54% | |
| 33 | JSPR | Jasper Therapeutics Inc | Stock-Other | 0.74% | — | — | |
| 34 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.73% | — | -26.22% | |
| 35 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.68% | +1.68% | NEW | |
| 36 | QTTB | Q32 Bio Inc | Stock-Other | 0.61% | +0.86% | NEW | |
| 37 | ✓ | Elevation Oncology Inc | Stock-Other | 0.58% | — | +366.00% | |
| 38 | ANNX | Annexon Inc | Stock-Other | 0.58% | — | -72.95% | |
| 39 | CMPS | Compass Pathways PLC | Stock-Other | 0.57% | -0.28% | — | |
| 40 | NKTREUR | Nektar Therapeutics | Stock-Other | 0.50% | — | — | |
| 41 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.47% | — | -71.91% | |
| 42 | SGMT | Sagimet Biosciences Inc-a | Stock-Other | 0.44% | — | — | |
| 43 | TRML | Tourmaline Bio Inc | Stock-Other | 0.43% | — | -62.29% | |
| 44 | IBIO | Ibio Inc | Stock-Other | 0.39% | +0.03% | — | |
| 45 | IFRX | InflaRx N.V. | Stock-Other | 0.38% | — | — | |
| 46 | 698 | Achilles Therapeutics Pl-adr | Stock-Other | 0.36% | — | — | |
| 47 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 0.36% | — | -45.38% | |
| 48 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.36% | — | -22.45% | |
| 49 | KOD | Kodiak Sciences Inc | Stock-Other | 0.35% | +1.13% | — | |
| 50 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.33% | — | — |
According to official SEC Form 13F filings, Ikarian Capital, LLC reported a total U.S. public equity portfolio value of $928.2M across 95 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q2 2024, Ikarian Capital, LLC's top holdings by market value included SRPT (10.0%)、CRNX (8.2%)、TARS (6.7%). The largest single position, SRPT, represented 10.0% of total portfolio value.
In Q2 2024, Ikarian Capital, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.